- Conditions
- Hepatitis C, Chronic
- Interventions
- BI201335, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 6
- States / cities
- San Francisco, California • Baltimore, Maryland • New York, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 366
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Ribavirin 200 mg tablets, COPEGUS™ 200 mg Tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
- Interventions
- ABT-450, ABT-072, Ribavirin, Ritonavir
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
- Drug
- Lead sponsor
- InterMune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Hepatitis, Chronic Active
- Interventions
- CPG10101, Control
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 13
- States / cities
- Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more
- Conditions
- Hepatitis C
- Interventions
- BI 201335, PegIFN/RBV
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Ribavirin, peginterferon alfa-2a [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 25
- States / cities
- Bakersfield, California • Pasadena, California • San Diego, California + 22 more
- Conditions
- Hepatitis C
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Memphis, Tennessee • Nashville, Tennessee
- Conditions
- Hepatitis C, Chronic
- Interventions
- peginterferon alfa-2a [Pegasys], Copegus
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
- Conditions
- Hepatitis C
- Interventions
- PF-00868554, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 9
- States / cities
- La Jolla, California • San Francisco, California • Orlando, Florida + 5 more
- Conditions
- Chronic Hepatitis C Infection, Fatty Liver
- Interventions
- Rosiglitazone and Pegasys/Ribavirin
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis C
- Interventions
- Peginterferon alfa-2a, Ribavirin, telaprevir
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hepatitis C
- Interventions
- SOF, VEL, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 40
- States / cities
- Long Beach, California • Los Angeles, California • Pasadena, California + 37 more
- Conditions
- Lung Diseases
- Interventions
- Zepatier, Epclusa
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 67 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Hepatitis C
- Interventions
- Taribavirin, Ribavirin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hepatitis C
- Interventions
- NOV-205
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Miami, Florida • Orlando, Florida + 3 more
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Pasadena, California + 31 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, peginterferon alfa-2a [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 75 more
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- ABT-267, ABT-450, ABT-333, Ritonavir, Ribavirin
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- La Jolla, California • Long Beach, California • Sacramento, California + 13 more
- Conditions
- Hepatitis C, Hepatitis C, Chronic
- Interventions
- thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
- Drug
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 54
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more
- Conditions
- Hepatitis C
- Interventions
- telaprevir, ribavirin, peginterferon alfa-2a
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more
- Conditions
- Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
- Interventions
- PEG-Interferon a-2b + Ribavirin
- Drug
- Lead sponsor
- Hepatitis Resource Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland